Loading...
•
Jun 30, 2021
TherapeuticsMD Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021.
Key Takeaways
TherapeuticsMD reported a 17% increase in total net product revenue compared to Q1 2021, reaching $23 million. Prescription growth was driven by ANNOVERA and IMVEXXY, with improved access to providers and increased telemedicine options. vitaCare signed a new customer, expanding its pipeline.
Total net product revenue increased by 17% over 1Q21 to $23 million.
ANNOVERA prescription growth was supported by improved access to providers and increased telemedicine options for patients.
IMVEXXY prescriptions grew by 8% over 1Q21, outpacing the VVA market.
Centers for Medicare and Medicaid Services recommended that ANNOVERA receive its own unique national J-Code that could be live as early as Q421.
TherapeuticsMD
TherapeuticsMD
Forward Guidance
TherapeuticsMD is focused on growing its products across all channels, with vitaCare building a foundation for future growth. The company is also evaluating investment into vitaCare, including potentially selling a minority stake.